Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | PTP4A3 | O75365 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2314543 | 1.00 | ALDH1A1 (0.32) | ALDH1A1POLBMAPTRECQLTDP1 | |
| SCHEMBL2380573 | 0.83 | KCNJ1 (0.34) | ALDH1A1POLBMAPTRECQLTDP1 | |
| SCHEMBL2380580 | 0.83 | KCNJ1 (0.34) | ALDH1A1POLBMAPTRECQLTDP1 | |
| SCHEMBL2377895 | 0.73 | MAOB (0.39) | — | |
| SCHEMBL2377900 | 0.73 | MAOB (0.39) | — | |
| SCHEMBL2381020 | 0.73 | CA12 (0.40) | ALDH1A1POLBMAPT | |
| SCHEMBL2381018 | 0.73 | CA12 (0.40) | ALDH1A1POLBMAPT | |
| SCHEMBL2048404 | 0.68 | KCNJ1 (0.36) | ALDH1A1MAPT | |
| SCHEMBL2380230 | 0.68 | KCNJ1 (0.36) | ALDH1A1MAPT | |
| SCHEMBL2379599 | 0.65 | BRD4 (0.35) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190288-A1 | DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) FOR USE IN TREATMENT OF DISEASES ASSOCIATED WITH A PTEN DEFICIENCY | MEDIVATION TECHNOLOGIES LLC | 2011-08-04 | — | — | US | claimed |
| US-20100035883-A1 | DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | LEAD THERAPEUTICS, INC. (US) | 2010-02-11 | — | — | US | claimed |
| US-11364241-B2 | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) | MEDIVATION TECHNOLOGIES LLC (US) | 2022-06-21 | — | — | US | disclosed |
| US-20210069191-A1 | DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | MEDIVATION TECHNOLOGIES LLC | 2021-03-11 | — | — | US | disclosed |
| US-10780088-B2 | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) | MEDIVATION TECHNOLOGIES LLC (US) | 2020-09-22 | — | — | US | disclosed |
| US-20200261454-A1 | DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | MEDIVATION TECHNOLOGIES LLC | 2020-08-20 | — | — | US | disclosed |
| US-10543209-B2 | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) | MEDIVATION TECHNOLOGIES LLC (US) | 2020-01-28 | — | — | US | disclosed |
| US-20190070189-A1 | DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) FOR USE IN TREATMENT OF DISEASES ASSOCIATED WITH A PTEN DEFICIENCY | BIOMARIN PHARMACEUTICAL INC. | 2019-03-07 | — | — | US | disclosed |
| US-20180117045-A1 | DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | MEDIVATION TECHNOLOGIES LLC | 2018-05-03 | — | — | US | disclosed |
| US-9820985-B2 | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) | MEDIVATION TECHNOLOGIES LLC (US) | 2017-11-21 | — | — | US | disclosed |
| EP-3241832-A1 | DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | Medivation Technologies, Inc. (US) | 2017-11-08 | — | — | EP | disclosed |
| US-20140066429-A1 | DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) FOR USE IN TREATMENT OF DISEASES ASSOCIATED WITH A PTEN DEFICIENCY | BIOMARIN PHARMACEUTICAL INC. (US) | 2014-03-06 | — | — | US | disclosed |
| EP-2326650-B1 | DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | BIOMARIN PHARM INC (US) | 2014-02-26 | — | — | EP | disclosed |
| US-8541403-B2 | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) for use in treatment of diseases associated with a PTEN deficiency | BIOMARIN PHARMACEUTICAL INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-20130190306-A1 | DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | BIOMARIN PHARMACEUTICAL INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-8420650-B2 | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) | BIOMARIN PHARMACEUTICAL INC. (US) | 2013-04-16 | — | — | US | disclosed |
| US-20110237581-A1 | DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | MEDIVATION TECHNOLOGIES LLC | 2011-09-29 | — | — | US | disclosed |
| US-8012976-B2 | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) | BIOMARIN PHARMACEUTICAL INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-20110190288-A1 | DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) FOR USE IN TREATMENT OF DISEASES ASSOCIATED WITH A PTEN DEFICIENCY | MEDIVATION TECHNOLOGIES LLC | 2011-08-04 | — | — | US | disclosed |
| US-20100035883-A1 | DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | LEAD THERAPEUTICS, INC. (US) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180117045-A1 | DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | PARP1, PARP2, PARP11 | ALDH1A1 326/4885POLB 19/4885MAPT 1286/4885 |
| US-10780088-B2 | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) | PARP1, PARP2, PARP11 | ALDH1A1 326/4885POLB 19/4885MAPT 1286/4885 |
| US-20190070189-A1 | DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) FOR USE IN TREATMENT OF DISEASES ASSOCIATED WITH A PTEN DEFICIENCY | PARP1, PARP2, PARP11 | ALDH1A1 879/4885POLB 23/4885MAPT 2574/4885 |
| US-20110237581-A1 | DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | PARP1, PARP2, PARP11 | ALDH1A1 326/4885POLB 19/4885MAPT 1286/4885 |
| US-11364241-B2 | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) | PARP1, PARP2, PARP11 | ALDH1A1 326/4885POLB 19/4885MAPT 1286/4885 |
| US-20130190306-A1 | DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | PARP1, PARP2, PARP11 | ALDH1A1 326/4885POLB 19/4885MAPT 1286/4885 |
| US-10543209-B2 | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) | PARP1, PARP2, PARP11 | ALDH1A1 326/4885POLB 19/4885MAPT 1286/4885 |
| US-20110190288-A1 | DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) FOR USE IN TREATMENT OF DISEASES ASSOCIATED WITH A PTEN DEFICIENCY | PARP1, PARP2, PARP11 | ALDH1A1 879/4885POLB 23/4885MAPT 2574/4885 |
| US-20100035883-A1 | DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | PARP1, PARP2, PARP11 | ALDH1A1 326/4885POLB 19/4885MAPT 1286/4885 |
| US-20140066429-A1 | DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) FOR USE IN TREATMENT OF DISEASES ASSOCIATED WITH A PTEN DEFICIENCY | PARP1, PARP2, PARP11 | ALDH1A1 879/4885POLB 23/4885MAPT 2574/4885 |
| US-20200261454-A1 | DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | PARP1, PARP2, PARP11 | ALDH1A1 326/4885POLB 19/4885MAPT 1286/4885 |
| US-20210069191-A1 | DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | PARP1, PARP2, PARP11 | ALDH1A1 326/4885POLB 19/4885MAPT 1286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.